Cadila Healthcare rose 3.10% to Rs 505.70 at 9:26 IST on BSE after the company said its Baddi facility got Establishment Inspection Report from US drug regulator.
Meanwhile, the S&P BSE Sensex was up 52.43 points, or 0.17% to 31,361.92.
On the BSE, 67,000 shares were traded in the counter so far, compared with average daily volumes of 1.21 lakh shares in the past one quarter. The stock had hit a high of Rs 510 so far during the day, which is also a record high for the counter. The stock had hit a low of Rs 501 so far during the day. The stock hit a 52-week low of Rs 305.05 on 24 June 2016.
The stock had outperformed the market over the past one month till 5 June 2017, rising 5.26% compared with 4.86% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 12.58% as against Sensex's 7.97% rise. The scrip had also outperformed the market in past one year, rising 51.93% as against Sensex's 16.92% rise.
The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.
Also Read
Cadila Healthcare announced after market hours yesterday, 5 June 2017, that its formulations manufacturing facility at Baddi in Himachal Pradesh has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA). This receipt of EIR indicates the successful closure of the inspection points (483s) raised based on the inspection carried out between 21 February 2017 to 1 March 2017.
Cadila Healthcare's consolidated net profit fell 32.2% to Rs 385.5 crore on 6.5% rise in net sales to Rs 2417.50 crore in Q4 March 2017 over Q4 March 2016.
Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
